<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">uzspbgmu</journal-id><journal-title-group><journal-title xml:lang="ru">Учёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. Павлова</journal-title><trans-title-group xml:lang="en"><trans-title>The Scientific Notes of the Pavlov University</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-4181</issn><issn pub-type="epub">2541-8807</issn><publisher><publisher-name>Academician I.P. Pavlov First St. Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/1607-4181-2015-22-2-32-35</article-id><article-id custom-type="elpub" pub-id-type="custom">uzspbgmu-86</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>HEALTH CARE ORGANIZATION</subject></subj-group></article-categories><title-group><article-title>ИСПОЛЬЗОВАНИЕ ПРОГРАММНОГО ОБЕСПЕЧЕНИЯ «DAWN AC» ДЛЯ КОНТРОЛЯ НАЗНАЧЕНИЯ ВАРФАРИНА В УСЛОВИЯХ СПЕЦИАЛИЗИРОВАННОЙ АНТИКОАГУЛЯНТНОЙ КЛИНИКИ</article-title><trans-title-group xml:lang="en"><trans-title>Using the software «DAWN AC» for control of dosing warfarin in the special anticoagulation clinics</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Напалкова</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Napalkova</surname><given-names>O. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Эмануэль</surname><given-names>В. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Emanuel</surname><given-names>V. L.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карпенко</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Karpenko</surname><given-names>M. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лапин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lapin</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова; Северо-западный федеральный исследовательский медицинский центр</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>30</day><month>06</month><year>2015</year></pub-date><volume>22</volume><issue>2</issue><fpage>32</fpage><lpage>35</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Напалкова О.С., Эмануэль В.Л., Карпенко М.А., Лапин С.В., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Напалкова О.С., Эмануэль В.Л., Карпенко М.А., Лапин С.В.</copyright-holder><copyright-holder xml:lang="en">Napalkova O.S., Emanuel V.L., Karpenko M.A., Lapin S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sci-notes.ru/jour/article/view/86">https://www.sci-notes.ru/jour/article/view/86</self-uri><abstract><p>Варфарин остается препаратом выбора для профилактики ишемического инсульта, в связи с чем становится актуальной оптимизация способа контроля дозы этого препарата. Целью работы была апробация компьютерного обеспечения для мониторинга терапии варфарина пациентов с мерцательной аритмией в условиях антикоагулянтной клиники. С помощью программного обеспечения наблюдались 6 человек с мерцательной аритмией, находящихся на лечении в дневном стационаре поликлиники в течение от 3 до 6 месяцев. Группу сравнения составили 11 пациентов с тем же диагнозом, сопоставимых по полу и возрасту. В результате исследования было установлено, что время пребывания МНО в терапевтическом диапазоне у пациентов, которым доза назначалась с помощью программного обеспечения, в два раза превышала таковое у пациентов, которым прием варфарина контролировал врач (p&lt;0,05). Полученные данные свидетельствуют о целесообразности использования программного обеспечения в мониторинге лечения варфарина, что увеличивает клиническую безопасность его применения.</p></abstract><trans-abstract xml:lang="en"><p>Warfarin remains the drug of choice for the prevention of ischemic stroke, thus optimization of methods of control of dosing this preparation becomes more topical. The aim of our study was to test computer software for monitoring anticoagulant therapy with warfarin in patients with atrial fibrillation based on the day anticoagulant hospital. A total of 6 people with atrial fibrillation undergoing treatment with warfarin in specialized outpatient clinics were monitored with the software for 3 to 6 months. At the same time, comparable 11 patients with atrial fibrillation were followed by experienced clinician. Both groups were matched by sex, age and clinical diagnosis. The comparison group consisted of 11 patients diagnosed with the same disease, of the same gender and age. We have found that in patients followed by anticoagulation software the time spent in the therapeutic INR range was twice the time in therapeutic range of patients in which the dosing and follow-up was done by experienced doctor (p&lt;0.05). The data indicate the possibility of using software to monitor warfarin therapy, which increases the clinical safety of its use.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>варфарин</kwd><kwd>кардиология</kwd><kwd>антикоагулянтная клиника</kwd><kwd>программное обеспечение</kwd><kwd>warfarin</kwd><kwd>anticoagulation clinic</kwd><kwd>cardiology</kwd><kwd>software</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Кропачева Е. С. Обеспечение безопастности длительной терапии варфарином: возможно ли возобновить лечение больного после гемморагического осложнения? // Рациональная фармокотерапия в кардиол. - 2009. - № 3.</mixed-citation><mixed-citation xml:lang="en">Кропачева Е. С. Обеспечение безопастности длительной терапии варфарином: возможно ли возобновить лечение больного после гемморагического осложнения? // Рациональная фармокотерапия в кардиол. - 2009. - № 3.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Хруслов М. В., Уханова И. Ю., Лобачев В. И. Оценка эффективности системы централизованного мониторинга лечения варфарином // Трудный пациент. - 2013.</mixed-citation><mixed-citation xml:lang="en">Хруслов М. В., Уханова И. Ю., Лобачев В. И. Оценка эффективности системы централизованного мониторинга лечения варфарином // Трудный пациент. - 2013.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ageno W., Johnson J. et al. A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy // Thromb Haemost. - 2000. - Vol. 83. - № 6. - Р. 849 - 852.</mixed-citation><mixed-citation xml:lang="en">Ageno W., Johnson J. et al. A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy // Thromb Haemost. - 2000. - Vol. 83. - № 6. - Р. 849 - 852.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Connolly S. J., Pogue J. et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range // Circulation. - 2008. - Vol. 118. - № 20. - P. 2029 - 2037.</mixed-citation><mixed-citation xml:lang="en">Connolly S. J., Pogue J. et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range // Circulation. - 2008. - Vol. 118. - № 20. - P. 2029 - 2037.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fuster V., Ryden L. E. et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) // Eur. Heart J. - 2006. - Vol. 27. - № 16. - P. 1979 - 2030.</mixed-citation><mixed-citation xml:lang="en">Fuster V., Ryden L. E. et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) // Eur. Heart J. - 2006. - Vol. 27. - № 16. - P. 1979 - 2030.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Holbrook A., Schulman S. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis. - 9th ed. // American College of Chest // Physicians Evidence-Based Clinical Practice Guidelines. Chest. - 2012. - Vol. 141 (Suppl. 2). - P. 152S - 184S.</mixed-citation><mixed-citation xml:lang="en">Holbrook A., Schulman S. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis. - 9th ed. // American College of Chest // Physicians Evidence-Based Clinical Practice Guidelines. Chest. - 2012. - Vol. 141 (Suppl. 2). - P. 152S - 184S.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jowett S., Bryan S. et al. The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study // J. Thromb. Haemost. - 2009. - Vol. 7. - № 9. - P. 1482-1490.</mixed-citation><mixed-citation xml:lang="en">Jowett S., Bryan S. et al. The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study // J. Thromb. Haemost. - 2009. - Vol. 7. - № 9. - P. 1482-1490.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lader E., Martin N. et al. Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do? // J. Clin. Pharm. Ther. - 2012. - Vol. 37 (4). - Р. 375 - 377.</mixed-citation><mixed-citation xml:lang="en">Lader E., Martin N. et al. Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do? // J. Clin. Pharm. Ther. - 2012. - Vol. 37 (4). - Р. 375 - 377.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mitra R., Marciello M. A. et al. Efficacy of computer-aided dosing of warfarin among patients in a rehabilitation hospital // Am. J. Phys. Med. Rehabil. - 2005. - Vol. 84. - № 6. - P. 423 - 427.</mixed-citation><mixed-citation xml:lang="en">Mitra R., Marciello M. A. et al. Efficacy of computer-aided dosing of warfarin among patients in a rehabilitation hospital // Am. J. Phys. Med. Rehabil. - 2005. - Vol. 84. - № 6. - P. 423 - 427.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Poller L., Keown M. et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage // J. Thromb Haemost. - 2008. - Vol. 6. - № 6. - P. 935 - 943.</mixed-citation><mixed-citation xml:lang="en">Poller L., Keown M. et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage // J. Thromb Haemost. - 2008. - Vol. 6. - № 6. - P. 935 - 943.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Poller L., Keown M. et al. A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program // Thromb. Haemost. - 2009. - Vol. 101. - № 3. - P. 487 - 494.</mixed-citation><mixed-citation xml:lang="en">Poller L., Keown M. et al. A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program // Thromb. Haemost. - 2009. - Vol. 101. - № 3. - P. 487 - 494.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rosendaal F. R., Cannegieter S. C. et al. A method to determine the optimal intensity of oral anticoagulant therapy // Thromb. Haemost. - 1993. - Vol. 69. - № 3. - P. 236 - 239.</mixed-citation><mixed-citation xml:lang="en">Rosendaal F. R., Cannegieter S. C. et al. A method to determine the optimal intensity of oral anticoagulant therapy // Thromb. Haemost. - 1993. - Vol. 69. - № 3. - P. 236 - 239.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
